Business Wire - Mylan Announces Approvals
Business &Medical Editors
PITTSBURGH–(BUSINESS WIRE)–Feb. 17, 2000
Mylan Laboratories Inc. (NYSE:MYL) announced today that it has received final approval to manufacture and market Terazosin Hydrochloride Capsules in 1mg, 2mg, 5mg, and 10mg strengths.
Terazosin is the generic equivalent to Hytrin(R), an alpha-1-selective adrenoceptor blocking agent manufactured and marketed by Abbott Laboratories Inc.
The product is indicated for the treatment of symptomatic Benign Prostatic Hyperplasia (BPH). It is also indicated for the treatment of hypertension.
The product is being manufactured in Mylan’s Morgantown, West Virginia facility. Shipment is beginning immediately.
Related Results
Boehringer, Abbott to co-promote Flomax - Brief Article
At work with… Stephen Neale
FDA Approves Three Hypertension Treatments.(Brief Article)(Statistical Data I…
Novartis settles dispute with FTC.(Brief Article)
FTC to Investigate Possible Pharma Collusion.(payoffs for delays of generic d…
Mylan has also been shipping Hydrochlorothiazide Capsules, 12.5mg, a first approval the company received at the end of January. The product is the generic equivalent to Watson’s Microzide(R), an antihypertensive.
COPYRIGHT 2000 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
